MedTrace Logo

A Study of AZD8233 in Participants With Dyslipidemia.

NCT04823611 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2024-12-24

Study results available
· View outcomes & findings →

Summary

A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia and this study consists of Part A , Part B and Part C. Part A is designed as a randomized, single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study. Part B is designed as a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study. Part C is designed as a randomized , single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study.

Conditions

Interventions

DRUG

Part A:Placebo

Placebo solution

DRUG

Part A:AZD8233

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

DRUG

Part B:Placebo

Placebo solution

DRUG

Part B:AZD8233

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

DRUG

Part C: Placebo

Placebo solution

DRUG

Part C: AZD8233

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2022-09-10
Completion
2022-09-10
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04823611 on ClinicalTrials.gov